After third generation EGFR-TKI resistance,where is the path of advanced NSCLC patients with EGFR mutations
10.3781/j.issn.1000-7431.2024.2404-0180
- VernacularTitle:第3代EGFR-TKI耐药后EGFR突变型晚期非小细胞肺癌患者的路在何方
- Author:
Ling PENG
1
;
Xiaorong DONG
1
Author Information
1. 华中科技大学同济医学院附属协和医院肿瘤中心,湖北 武汉 430022;华中科技大学同济医学院附属协和医院肿瘤放射治疗研究所,湖北 武汉 430022;肿瘤精准放射治疗湖北省重点实验室,湖北 武汉 430022
- Publication Type:Journal Article
- Keywords:
Advanced non-small cell lung cancer;
Epidermal growth factor receptor;
Tyrosine kinase inhibitor;
Drug resistance
- From:
Tumor
2024;44(6):566-573
- CountryChina
- Language:Chinese
-
Abstract:
The epidermal growth factor receptor(EGFR)gene is the most common driver gene in non-small cell lung cancer(NSCLC).The third generation tyrosine kinase inhibitor(TKIs)targeting EGFR mutations are the preferred first-line treatment choice for EGFR-mutated advanced NSCLC patients.Although third-generation EGFR-TKIs have provided durable survival benefits for patients,the emergence of drug resistance poses significant challenges for subsequent treatment.Currently,the mechanisms of resistance to the third-generation EGFR-TKIs and corresponding treatment strategies are under investigation.The resistance mechanisms to third-generation EGFR-TKIs can be classified into two types:EGFR-dependent and EGFR-independent.EGFR-dependent resistance mechanisms represent acquired EGFR mutations including C797S.EGFR-independent resistance mechanisms include activation of bypass signaling pathways,alterations in cell cycle-related genes,and phenotypic transformation.Researchers are exploring potential post-resistant treatment approaches such as fourth-generation EGFR-TKIs,combination therapy,chemotherapy,and immunotherapy to overcome these resistance mechanisms.Through in-depth study of resistance mechanisms and the exploration of novel treatment strategies,we hope to overcome the resistance to third-generation EGFR-TKIs,providing more treatment options and better clinical outcomes for EGFR-mutated advanced NSCLC patients.
